C
CABA
Cabaletta Bio, Inc.
3.765
-0.005-0.13%Opening15:02 05/29 EDT
OPEN/PREV CLOSE3.800/3.770
TODAY RANGE3.660-3.880
VOL1.54M
MARKET CAP613.90M
52 WEEK RANGE1.260-4.230
AVG VOL (3M)3.01M
% TURNOVER0.95%
TURNOVER--
P/E (TTM)-1.9221
% RANGE5.84%
EPS(TTM)-1.9588
P/E(FORWARD)-2.8308
P/B4.057
BVPS0.9280
DIVIDEND--
P/S2,859.09
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP607.71M
SHARES OUTSTANDING163.05M
NEXT EARNINGS08/05-08/10
FREE FLOAT161.41M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·05/15 13:27
Morgan Stanley Remains a Buy on Cabaletta Bio (CABA)
Dow Jones·05/15 13:15
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Dow Jones·05/15 13:15
Cabaletta Bio Price Target Raised to $4.00/Share From $2.00 by Wells Fargo
Benzinga·05/15 13:06
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4
TipRanks·05/15 11:10
Wells Fargo Gives a Hold Rating to Cabaletta Bio (CABA)
TipRanks·05/15 11:05
Cabaletta Bio (CABA) Receives a Buy from Guggenheim
Reuters·05/15 10:29
CABALETTA BIO, INC. <CABA.O>: WELLS FARGO RAISES TARGET PRICE TO $4 FROM $2
Seeking Alpha·05/14 14:46
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
TipRanks·05/14 14:21
Cabaletta Bio presents new clinical data for rese-cel
TipRanks·05/14 12:08
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
TipRanks·05/14 11:40
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
Benzinga·05/14 11:23
Cabaletta Bio Q1 EPS $(0.39), Inline
Same Industry
Name/Symbol
Change%
Price